IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma

American Journal of Clinical Pathology

Volumn 133, Issue 6, 2010, Pages 899-908

  Mhawech Fauceglia, Paulette ^a   Herrmann, Francois R ^b   Rai, Har ^a   Tchabo, Nana ^a   Lele, Shashikant ^a   Izevbaye, Iyare ^a   Odunsi, Kunle ^a   Cheney, Richard T ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b University Hospital   (Switzerland)

Author keywords

Endometrioid adenocarcinoma; Immunohistochemistry; Predictive diagnostic value; Serous carcinoma; Uterine corpus

Indexed keywords

BETA CATENIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN IMP3; PROTEIN P53; RIBONUCLEOPROTEIN; UNCLASSIFIED DRUG; IMP3 PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; RNA BINDING PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; ENDOMETRIOID ADENOCARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE SEROUS CARCINOMA; UTERUS CARCINOMA; CYSTADENOCARCINOMA; DIFFERENTIAL DIAGNOSIS; ENDOMETRIOID CARCINOMA; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; UTERUS CANCER;

ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MIDDLE AGED; PTEN PHOSPHOHYDROLASE; RETROSPECTIVE STUDIES; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS;

EID: 77952959702     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPQDQXJ4FNRFQB     Document Type: Article

References (31)

1. Kitchener HC, Trimble EL; the Endometrial Cancer Working Group of the Gynecologic Cancer Intergroup. Endometrial cancer state of the science meeting. Int J Gynecol Cancer. 2009;119:134-140.
2. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification and targeted therapies. Cancer Control. 2009;16:8-13.
3. Boruta DM Jr, Gehrig PA, Groben PA, et al. Uterine serous and grade 3 endometrioid carcinomas. Cancer. 2004;101:2214-2221.
4. Naumann RW. Uterine papillary serous carcinomas: state of the state. Curr Oncol Rep. 2008;10:505-511.
5. Faratian D, Stillie A, Busby-Earle RM, et al. A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome. Int J Gynecol Cancer. 2006;16:972-978. (Pubitemid 43886712)
6. Koul A, Willen R, Bendahl P-O, et al. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer. 2002;94:2369-2379. (Pubitemid 34457118)
7. Silverberg SG. The endometrium: pathologic principles and pitfalls. Arch Pathol Lab Med. 2007;131:372-382.
8. Reid-Nicholson M, Iyengar P, Hummer AJ, et al. Immunophenotyping diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol. 2006;19:1091-1100. (Pubitemid 44106724)
9. Halperin R, Zehavi S, Habler L, et al. Uterine papillary serous carcinoma (pure and mixed type) compared with moderately and poorly differentiated endometrioid carcinoma: a clinicopathologic study. Eur J Gynaecol Oncol. 2001;22:122-126.
10. Behrens J. Cadherins and catenins: role in signal transduction and tumor progression. Cancer Metastasis Rev. 1999;8:15-30. (Pubitemid 29411089)
11. Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14:1837-1851.
12. Schlosshauer PW, Ellenson LH, Soslow RA. β-Catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Pathol. 2002;15:1032-1037.
13. Nei H, Saito T, Yamasaki H, et al. Nuclear localization of beta-catenin in normal and carcinogenic endometrium. Mol Carcinog. 1999;25:207-218. (Pubitemid 29319286)
14. Lomo L, Nucci MR, Lee KR, et al. Histologic and immunohistochemical decision-making in endometrial adenocarcinoma. Mod Pathol. 2008;21:937-942.
15. Egan JA, Ionescu MC, Eapen E, et al. Differential expression of WT1 and p53 in serous and endometrial carcinomas of the endometrium. Int J Gynecol Pathol. 2004;23:119-122.
16. Demopoulos RI, Mesia AF, Mittal K, et al. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis. Int J Gynecol Pathol. 1999;18:233-237.
17. Bussaglia E, del Rio E, Matias-Guiu X, et al. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. Hum Pathol. 2000;31:312-317.
18. Kong D, Suzuki A, Zou TT, et al. PTEN1 is frequently mutated in primary endometrial carcinomas [letter]. Nat Genet. 1997;17:143-144.
19. Pallares J, Bussaglia E, Matrinez-Guitarte JL, et al. Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison with molecular abnormalities. Mod Pathol. 2005;18:719-727.
20. Macwhinnie N, Monaghan H. The use of p53, PTEN, and C-erbB2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma. Int J Gynecol Cancer. 2004;14:938-946. (Pubitemid 39238183)
21. Nielsen J, Christiansen J, Lykke-Andersen J, et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 1999;9:1262-1270. (Pubitemid 29046868)
22. Li C, Zota V, Woda BA, et al. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod Pathol. 2007;20:1263-1268. (Pubitemid 350126850)
23. Zheng W, Yi X, Fadare O, et al. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol. 2008;32:304-315. (Pubitemid 351172146)
24. Announcements: FIGO stages: 1988 revision. Gynecol Oncol. 1989;35:125-127.
25. Silverberg SG, Kurman RJ, Nogales F, et al. WHO histological classification of tumours of the uterine corpus. In: Tavassoli FA, Devilee P, eds. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003:221-232. World Health Organization Classification of Tumours.
26. Fader AN, Starks D, Gehrig PA, et al. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2009;115:244-248.
27. Darvishian F, Hummer AJ, Thaler HT, et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol. 2004;28:1568-1578. (Pubitemid 39564961)
28. Li C, Rock KL, Woda BA, et al. IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16 expression. Mod Pathol. 2007;20:242-247.
29. Jian Z, Chu P, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 2006;7:556-564.
30. Gress TM, Muller-Pillasch F, Geng M, et al. A pancreatic cancer-specific expression profile. Oncogene. 1996;13:1819-1830.
31. Al Kushi A, Lim P, Aquino-Parsons C, et al. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of the endometrium. Mod Pathol. 2002;15:365-371.